CORE Biomedicine$21M
Precision cancer medicines targeting the biological programs that define cancer-cell identity and sustain tumour growth.
UTokyo Innovation Platform Co., Elikon Venture
Startup Funding News
New startup rounds, lead investors and the businesses behind the funding.
2 rounds · $336M disclosed · $168M median
| Company | Amount | Stage / sector | Lead investor | Announced |
|---|---|---|---|---|
| CORE Biomedicine Precision cancer medicines targeting the biological programs that define cancer-cell identity and sustain tumour growth. | $21M | Series A Cancer therapeutics | UTokyo Innovation Platform Co., Elikon Venture | |
| AdvanCell Develops cancer treatments that deliver alpha radiation to tumor cells, supported by its own Lead-212 isotope supply and manufacturing platform. | $315M | Series C+ Radiopharmaceuticals | Ally Bridge Group, Alpha Wave Global |
AdvanCell$315M
Develops cancer treatments that deliver alpha radiation to tumor cells, supported by its own Lead-212 isotope supply and manufacturing platform.
Ally Bridge Group, Alpha Wave Global
02 / Perspective
Reports & briefings
monthly briefing
September 2026 Startup Funding Report
84 sourced rounds, with company profiles and participating investors.
weekly briefing
Sep 21 – 27, 2026 Startup Funding Weekly
27 sourced rounds, with company profiles and participating investors.
weekly briefing
Sep 14 – 20, 2026 Startup Funding Weekly
6 sourced rounds, with company profiles and participating investors.
03 / Investors
Active investors
| Investor | Rounds | Led | Recent investments |
|---|---|---|---|
| 01Y Combinator | 28 | 2 | SpottConveo |
| 02Accel | 26 | 10 | ArmadinArivihan |
| 03Lightspeed Venture Partners | 26 | 6 | Temporal TechnologiesNeko Health |
| 04General Catalyst | 25 | 3 | General IntuitionDwelly |